ANAPTYSBIO, INC (ANAB) Form 8-K — May 11, 2026
On May 11, 2026, AnaptysBio, Inc. announced the appointment of Christopher M. Murphy as Chief Financial Officer, effective immediately. Mr.
Key figures
- Total Debt
- 0
- Cash Position
- 0
- Shares Outstanding
- 0
- Equity Grant
- $1,750,000
- Consulting Fee
- $42,916.66
- Vesting Schedule
- 1/4 on the first anniversary, 1/4 in equal annual installments over the next 3 years
- Bonus Opportunity
- 40% of total annual consulting fees
- Director RSUGrant
- 11,250 restricted stock units
- Director Vesting Schedule
- over a three-year period
Price after filing
1 day: -3.4%7 days: -13.5%30 days: -24.0%
Close on the filing date to close N calendar days later (from $67.92). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.